Go or no go? A busy month ahead for US FDA decisions
June will be hectic for the US regulator, with many approval decisions due, including one for subcutaneous Arzerra in multiple sclerosis and Tazverik in follicular…
Go or no go? Abbvie, Roche and Kala await key decisions
One of the biggest drugs of the year, Abbvie’s Jak inhibitor upadacitinib, could get the nod in August.
No news equals bad news for Nabriva and Heron
Manufacturing issues prompt the US regulator to knock back projects from Nabriva and Heron Therapeutics, both of which insist that the problems are easily solvable.
Go or no go? Abbvie, Glaxo and Heron await FDA verdicts
Notable US regulatory decisions due in April feature a major pipeline hope from Abbvie, a non-opioid pain medication from Heron and Glaxo’s two-pill HIV regimen.
